Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLR1A | O95602 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5417245 | 0.88 | SLC6A3 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5404025 | 0.85 | SLC6A3 (0.41) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5418659 | 0.81 | SLC6A2 (0.43) | CYP2C19SLC6A2SLC6A4SLC6A3CYP2D6 | |
| SCHEMBL5392573 | 0.81 | HTR7 (0.44) | — | |
| SCHEMBL5402981 | 0.80 | SLC6A2 (0.38) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5402539 | 0.80 | MDM2 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5406382 | 0.79 | SLC6A3 (0.40) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5408891 | 0.79 | ALDH1A1 (0.37) | CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5398635 | 0.78 | KCNA5 (0.40) | SMN1; SMN2 | |
| SCHEMBL5398006 | 0.76 | KCNA5 (0.40) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169782-B2 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2007-01-30 | — | — | US | disclosed |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | EURO-CELTIQUE S.A. (LU) | 2004-09-09 | — | — | US | disclosed |
| EP-1417187-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2004-05-12 | — | — | EP | disclosed |
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | EURO-CELTIQUE, S.A. | 2003-06-12 | — | — | US | disclosed |
| WO-2003008398-A1 | ARYL SUBSTITUTED THIAZOLIDINONES AND THE USE THEREOF | EURO-CELTIQUE S.A. (LU) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109521-A1 | Aryl substituted thiazolidinones and the use thereof | CACNA1S, CACNA1I, CACNA1C | POLR1A 2399/4885CYP1A2 1236/4885CYP2C19 3051/4885 |
| US-20040176364-A1 | Aryl substituted thiazinidinones and the use thereof | CACNA1S, CACNA1I, NLN | POLR1A 2489/4885CYP1A2 1316/4885CYP2C19 3102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.